Cover Image

Discovery and development of anti-prostate cancerous agents from natural products /

Discovery and Development of Anti-Prostate Cancer Agents from Natural Products presents cutting-edge research advances in the field of bioactive natural products and natural drug formulations. This new volume in the Natural Products Drug Discovery series focuses on molecules of natural origin and th...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Brahmachari, Goutam (Editor)
Format: eBook
Language:English
Published: Amsterdam, Netherlands : Elsevier, 2025.
Series:Natural product drug discovery
Subjects:
Prostate > Cancer > Chemotherapy > Technological innovations.
Natural products.
Prostate > Cancer > Chimiothérapie > Innovations.
Produits naturels.
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Front Cover
  • Discovery and Development of Anti-Prostate Cancerous Agents from Natural Products
  • Copyright Page
  • Dedication
  • Contents
  • List of contributors
  • About the editor
  • Foreword
  • Preface
  • 1 Discovery and development of antiprostate cancerous agents from natural products: an overview
  • 1.1 Introduction
  • 1.2 An overview of the book
  • 1.2.1 Chapter 2
  • 1.2.2 Chapter 3
  • 1.2.3 Chapter 4
  • 1.2.4 Chapter 5
  • 1.2.5 Chapter 6
  • 1.2.6 Chapter 7
  • 1.2.7 Chapter 8
  • 1.2.8 Chapter 9
  • 1.2.9 Chapter 10
  • 1.2.10 Chapter 11
  • 1.2.11 Chapter 12
  • 1.2.12 Chapter 13
  • 1.3 Concluding remarks
  • 2 Molecular signaling of prostate cancer chemoprevention by natural products: current perspectives and future directions
  • 2.1 Introduction
  • 2.2 Overview of the molecular basis of prostate cancer
  • 2.2.1 Molecular basis of androgen-dependent prostate cancer
  • 2.2.2 Molecular basis of castration-resistant prostate cancer and the tumor microenvironment
  • 2.2.2.1 Canonical androgen receptor signaling
  • 2.2.2.1.1 Common alterations in androgen receptor
  • 2.2.2.1.1.1 Androgen receptor amplification or overexpression
  • 2.2.2.1.1.2 Androgen receptor mutations
  • 2.2.2.1.1.3 Truncated androgen receptor
  • 2.2.2.1.2 Androgen receptor activation by androgens converted from adrenal androgens or synthesized intratumorally via the ...
  • 2.2.2.1.2.1 Dihydrotestosterone intratumorally via the de novo route
  • 2.2.2.1.2.2 Dihydrotestosterone converted from adrenal androgens
  • 2.2.2.1.3 Alterations in cofactors of the androgen receptor pathway in castration-resistant prostate cancer
  • 2.2.2.2 Nonnuclear androgen receptor signaling
  • 2.2.2.2.1 PI3K/AKT signaling pathway
  • 2.2.2.2.2 Src signaling pathway
  • 2.2.2.2.3 MAPKs signaling pathway
  • 2.2.2.2.4 JAK-STAT3 signaling pathway
  • 2.2.2.2.5 Ca2+ signaling pathway.
  • 2.3 Natural compounds with potential to treat prostate cancer
  • 2.3.1 Natural compounds modulating the androgen receptor axis
  • 2.3.2 Natural compounds affecting proliferation
  • 2.3.3 Natural compounds inducing canonical and noncanonical cell deaths
  • 2.3.4 Natural compounds impairing metabolism
  • 2.3.5 Natural compounds inhibiting invasion
  • 2.3.6 Natural compounds reducing angiogenesis
  • 2.3.7 Natural compounds targeting cancer stem cells
  • 2.4 Concluding remarks
  • Abbreviations
  • References
  • 3 Withanolides as anti-prostate cancer agents of promise
  • 3.1 Introduction
  • 3.2 Mechanism of action for treatment of prostate cancer
  • 3.2.1 Reactive oxygen species signaling pathway
  • 3.2.2 Cytoskeletal organizing and structural proteins
  • 3.2.3 Proteasomal inhibition
  • 3.2.4 Inhibition of mitosis
  • 3.2.5 Transcription factors
  • 3.2.6 Metabolic enzymes
  • 3.3 Targeting signaling pathways of prostate cancer
  • 3.3.1 Targeting androgen receptor signaling
  • 3.3.2 Bone microenvironment of prostate cancer
  • 3.3.3 Targeting prostate-specific membrane antigen
  • 3.3.4 Targeting DNA repair pathways
  • 3.3.5 Targeting the cell cycle
  • 3.3.6 Targeting the PI3K/AKT/mTOR signaling axis
  • 3.3.7 Targeting epigenetic marks
  • 3.4 Withanolides
  • 3.4.1 Anti-prostate cancer activity of withanolides isolated from Physalis species
  • 3.4.1.1 Withanolides from Physalis angulata L
  • 3.4.1.2 Withanolides isolated from Physalis crassifolia L
  • 3.4.1.3 Withanolides isolated from Physalis pubescens L
  • 3.4.1.4 Withanolides from Physalis peruviana
  • 3.4.2 Anti-prostate cancer activity of withanolides isolated from Withania species
  • 3.5 Molecular targets of prostate cancer for withaferin A
  • 3.5.1 Mediated cell cycle inhibition by withaferin A
  • 3.5.2 Proteasomal inhibition by withaferin A
  • 3.5.3 Angiogenesis inhibition by withaferin A.
  • 3.5.4 Withaferin A-induced apoptosis in prostate cancer cells
  • 3.5.5 Role of Par-4 in the apoptotic action of withaferin A
  • 3.5.6 Withaferin A-induced mitotic catastrophe and growth arrest
  • 3.5.7 Withaferin A inhibits AKT-mediated epithelial-to-mesenchymal transition in prostate tumors
  • 3.5.8 Nonspecific targets of withaferin A in prostate cancer
  • 3.6 Concluding remarks
  • Acknowledgments
  • Abbreviations
  • References
  • 4 A brief sketch on antiprostate cancer activity of plant phenolics
  • 4.1 Introduction
  • 4.1.1 The prostate
  • 4.1.2 Prostate-related disorders
  • 4.1.3 Types of prostate cancer
  • 4.1.4 Signs and symptoms
  • 4.1.5 Causes
  • 4.1.6 Risk factors
  • 4.1.7 Diagnosis
  • 4.1.7.1 Digital rectal exam
  • 4.1.7.2 Prostate-specific antigen test
  • 4.1.7.3 Ultrasound
  • 4.1.7.4 Prostate-specific membrane antigen-positron emission tomography scan
  • 4.1.7.5 Magnetic resonance imaging
  • 4.1.7.6 Prostate biopsy
  • 4.1.8 Stages of prostate cancer
  • 4.1.8.1 Gleason score for grading prostate cancer
  • 4.2 Androgens and prostate cancer
  • 4.2.1 Changes in androgen receptors in prostate cancer
  • 4.3 Prostate cancer cell lines
  • 4.4 Epigenetics aspects in prostate cancer progression
  • 4.5 Prostate cancer rodent models
  • 4.6 Treatment options
  • 4.6.1 Active surveillance
  • 4.6.2 Surgery
  • 4.6.3 Radical prostatectomy
  • 4.6.4 Radiation and Radiopharmaceutical therapy
  • 4.6.5 Hormone therapy
  • 4.6.6 Chemotherapy
  • 4.7 Plant phenolics as antiprostate cancer agents
  • 4.7.1 Simple phenols
  • 4.7.1.1 Ardisenone
  • 4.7.1.2 Capsaicin
  • 4.7.1.3 Carvacrol
  • 4.7.1.3.1 Pharmacokinetics of Carvacrol in rabbits
  • 4.7.1.3.2 Safety profile of carvacrol
  • 4.7.1.4 Curcumin
  • 4.7.1.4.1 Combination studies
  • 4.7.1.4.1.1 Curcumin and genistein
  • 4.7.1.4.1.2 Curcumin and soy isoflavones
  • 4.7.1.5 Denbinobin
  • 4.7.1.6 10-Gingerol.
  • 4.7.1.7 Gossypol
  • 4.7.1.8 Garcinol
  • 4.7.1.8.1 Mode of action
  • 4.7.1.8.2 In vivo efficacy
  • 4.7.1.9 Phenolics from Dalbergia
  • 4.7.1.10 Hydroxychavicol
  • 4.7.1.11 Alpha-mangostin
  • 4.7.1.12 Narciclasine
  • 4.7.1.13 Piceatannol
  • 4.7.1.14 Plumbagin
  • 4.7.1.15 Pterostilbene
  • 4.7.1.16 Resveratrol
  • 4.7.1.17 Alpha-tocopherol
  • 4.7.2 Phenolic acids
  • 4.7.2.1 Amorfrutin C
  • 4.7.2.2 Gallic acid
  • 4.7.2.3 Protocatechuic acid
  • 4.7.2.4 Sinapic acid
  • 4.7.3 Phenolic chalcones
  • 4.7.3.1 Phenolic chalcones from prairie clovers
  • 4.7.3.2 Dihydrochalcone
  • 4.7.3.3 Pinocembrin and licochalcone A
  • 4.7.4 Flavonoids
  • 4.7.4.1 Apigenin
  • 4.7.4.1.1 Mode of action
  • 4.7.4.2 Genistein
  • 4.7.4.2.1 Mode of action
  • 4.7.4.3 Hesperidin
  • 4.7.5 Lignans and neolignans
  • 4.7.5.1 Lignans from Austrobaileya scandens
  • 4.7.5.2 Honokiol
  • 4.7.5.3 Isosilybin A and Isosilybin B
  • 4.7.5.4 Silybinin
  • 4.7.6 Miscellaneous phenolics
  • 4.7.6.1 Phenolics from hops
  • 4.7.6.2 Phenolics from evening primrose (Oenothera paradoxa)
  • 4.7.6.3 Phenolics from Vaccinium spp
  • 4.7.7 Dietary polyphenols as antiprostate cancer agents
  • 4.7.7.1 Oligomeric proanthocyanidin complexes
  • 4.7.7.2 Cancer chemoprevention by Pomegranate fruit juice phenolics
  • 4.7.7.2.1 Mode of action
  • 4.7.7.3 Phenolics from Punica granatum
  • 4.7.7.3.1 Mode of action
  • 4.7.7.4 Pomegranate fruit juice
  • 4.7.7.5 Grape seed proanthocyanidins as antiprostate cancer agents
  • 4.7.7.5.1 Mode of action
  • 4.7.7.6 Grape seed polyphenolics
  • 4.7.7.7 Broccoli sprouts
  • 4.7.7.8 Phytoestrogens of leopard lily
  • 4.7.7.9 Tea polyphenols
  • 4.7.7.9.1 Pharmacokinetics
  • 4.7.7.9.2 Metabolites
  • 4.7.7.9.3 Soy and isoflavonoids
  • 4.7.7.9.4 Black walnut
  • 4.7.7.9.5 Animal studies
  • 4.7.7.9.6 Human studies
  • 4.7.7.10 Phytoestrogen from Blackberry Lily
  • 4.7.7.11 Raspberry phenolics.
  • 4.8 Plant phenolics under clinical trial studies
  • 4.9 Future prospects
  • 4.10 Concluding remarks
  • Acknowledgment
  • Abbreviations
  • References
  • 5 Role of lycopene in maintaining human prostate health
  • 5.1 Introduction
  • 5.2 Prostate-specific antigen
  • 5.2.1 Measurement and interpretation of prostate-specific antigen levels
  • 5.3 Beneficial effects of lycopene in maintaining prostate health
  • 5.3.1 Impact of lycopene on prostate-specific antigen levels
  • 5.3.2 Benign prostatic hyperplasia
  • 5.4 Concluding remarks
  • Funding
  • Conflict of interests
  • References
  • 6 Anti-prostate cancer potential of some selected natural alkaloids
  • 6.1 Introduction
  • 6.2 Alkaloids with anti-prostate cancer potential
  • 6.2.1 Capsaicin
  • 6.2.2 Berberine
  • 6.2.3 Tetrandrine
  • 6.2.4 Fangchinoline
  • 6.2.5 Brassinin
  • 6.2.6 Evodiamine
  • 6.2.7 Mahanine
  • 6.2.8 Solanine
  • 6.3 Concluding remarks
  • Abbreviations
  • References
  • 7 Triterpenes as promising antiprostate cancer agents
  • 7.1 Introduction
  • 7.1.1 Prostate cancer
  • 7.1.2 Natural triterpenes
  • 7.2 Triterpenoids and cancer
  • 7.3 Significant triterpenoids from natural sources: promising role against prostate cancer
  • 7.3.1 Ursolic acid
  • 7.3.2 Oleanolic acid
  • 7.3.3 Corosolic acid
  • 7.3.4 Celastrol
  • 7.3.5 Lupeol
  • 7.3.6 Nummularic acid
  • 7.3.7 Other triterpenoids
  • 7.4 Concluding remarks
  • Abbreviations
  • References
  • 8 Flavones and prostate cancer
  • 8.1 Introduction
  • 8.2 Prostate cancer
  • 8.2.1 Etiology
  • 8.2.2 Diagnosis and treatment
  • 8.3 Selected natural flavones with antiprostate cancer activity
  • 8.3.1 Apigenin
  • 8.3.1.1 Antiprostate cancer effect
  • 8.3.1.2 Therapeutic challenges
  • 8.3.2 Chrysin
  • 8.3.2.1 Antiprostate cancer effect
  • 8.3.2.2 Therapeutic challenges
  • 8.3.3 Luteolin
  • 8.3.3.1 Antiprostate cancer effect
  • 8.3.3.2 Therapeutic challenges.